ArticleCancers2018
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02555735 (Evaluation of Exceptional Responders With Solid Tumor Cancer), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Exceptional Responders With Solid Tumor Cancer
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.Cancer · 2022Trial
- The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025Review
- Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report.Frontiers in oncology · 2025Article
- Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- Article
- ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.Cancers · 2022Article
- Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities.Cancers · 2022Review
- Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor.Pharmacology research & perspectives · 2022Article
- Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.International journal of molecular sciences · 2022Review
- Pancreas cancer: Therapeutic trials in metastatic disease.Journal of surgical oncology · 2021Review
- Predicting Gemcitabine Delivery byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells.OncoTargets and therapy · 2021Review
- The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Previous studies have shown that pharmacogenomic modeling of circulating tumor and invasive cells (CTICs) can predict response of pancreatic ductal adenocarcinoma (PDAC) to combination chemotherapy, predominantly 5-fluorouracil-based. We hypothesized that a similar approach could be developed to predict treatment response to standard frontline gemcitabine with nab-paclitaxel (G/nab-P) chemotherapy. Gene expression profiles for responsiveness to G/nab-P were determined in cell lines and a test set of patient samples. A prospective clinical trial was conducted, enrolling 37 patients with advanced PDAC who received G/nab-P. Peripheral blood was collected prior to treatment, after two months of treatment, and at progression. The CTICs were isolated based on a phenotype of collagen invasion. The RNA was isolated, cDNA synthesized, and qPCR gene expression analyzed. Patients were most closely matched to one of three chemotherapy response templates. Circulating tumor and invasive cells'
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.